Back HCV Treatment

HCV Treatment

EASL Paris: 100% Cure Rate with AL-335, Odalasvir, and Simeprevir for 6 or 8 Weeks

A triple regimen containing 2 experimental hepatitis C drugs -- AL-335 and odalasvir -- plus simeprevir taken for either 6 or 8 weeks cured all previously untreated, non-cirrhotic patients with HCV genotype 1 in a small study, while a dual regimen without simeprevir cured 90%, according to findings presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.

alt

Read more:

EASL Issues New Hepatitis C Treatment Recommendations For All Genotypes

The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last week in Paris. The updated guidelines now include highly effective interferon-free options for all hepatitis C virus (HCV) genotypes and for the most challenging patients.

alt

Read more:

INHSU 2016: HCV Treatment Effective and May Work as Prevention for People Who Inject Drugs

Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users -- with cure rates exceeding 90% -- and treating enough of this population could reduce transmission or even bring a halt to local epidemics, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo.

alt

Read more:

INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment

People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a greater emphasis on post-treatment prevention may be needed, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this month in Oslo.

alt

Read more:

INHSU 2016: Hepatitis C Vaccine Development Shows Progress but Scientific Barriers Remain

An effective vaccine may be necessary to eliminate hepatitis C virus (HCV), but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo. One promising prime-boost viral vector vaccine is currently in clinical trials.

alt

Read more: